Intense Pulsed Light (IPL) and Meibomian Gland Expression to Treat Ocular Rosacea Secondary to Inactive Chronic Ocular Graft Versus Host Disease (GVHD)

Location:

Phoenix/Scottsdale, Ariz.

Trial status:

Open for Enrollment

Why is this study being done?

Is Intense Pulsed Light (IPL) treatment and eyelid meibomian gland manual expression safe and effective for allogeneic stem cell transplant patients with ocular rosacea in the setting of quiescent graft-versus-host disease?

Who is eligible to participate?

Inclusion Criteria: - Ocular rosacea with inactive GVHD Exclusion Criteria: - Active GVHD - Facial laser treatment - Accutane exposure - Inability to wear sun protection factor (SPF) 30 sunscreen and avoid sun exposure - Inability to meet study requirements

Last updated:

2/17/2014

NCT ID:

NCT02066051

IRB Number:

13-003814